| HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now I Schlam, SM Swain NPJ breast cancer 7 (1), 56, 2021 | 207 | 2021 |
| Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler H Bergholtz, JM Carter, A Cesano, MCU Cheang, SE Church, P Divakar, ... Cancers 13 (17), 4456, 2021 | 79 | 2021 |
| Overcoming resistance to HER2-directed therapies in breast cancer I Schlam, P Tarantino, SM Tolaney Cancers 14 (16), 3996, 2022 | 50 | 2022 |
| Carfilzomib: a cause of drug associated thrombotic microangiopathy I Qaqish, IM Schlam, HA Chakkera, R Fonseca, J Adamski Transfusion and Apheresis Science 54 (3), 401-404, 2016 | 43 | 2016 |
| PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma S Panchabhai, I Schlam, S Sebastian, R Fonseca Leukemia 31 (4), 991-994, 2017 | 34 | 2017 |
| How I treat HER2-low advanced breast cancer I Schlam, SM Tolaney, P Tarantino The Breast 67, 116-123, 2023 | 31 | 2023 |
| The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling I Schlam, SE Church, TD Hether, K Chaldekas, BM Hudson, AM White, ... Journal of translational medicine 19, 1-14, 2021 | 29 | 2021 |
| Filling the gap after CDK4/6 inhibitors: novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer A Mittal, C Molto Valiente, F Tamimi, I Schlam, S Sammons, SM Tolaney, ... Cancers 15 (7), 2015, 2023 | 22 | 2023 |
| Immune checkpoint inhibitors in the treatment of breast cancer brain metastases I Schlam, ME Gatti-Mays The oncologist 27 (7), 538-547, 2022 | 18 | 2022 |
| Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy MI Jarman, K Lee, A Kanevsky, S Min, I Schlam, C Mahida, A Huda, ... BMC hematology 17, 1-6, 2017 | 17 | 2017 |
| Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2 I Schlam, R Moges, S Morganti, SM Tolaney, P Tarantino Critical Reviews in Oncology/Hematology 190, 104090, 2023 | 15 | 2023 |
| Managing adverse events of sacituzumab govitecan I Schlam, P Tarantino, SM Tolaney Expert Opinion on Biological Therapy 23 (11), 1103-1111, 2023 | 12 | 2023 |
| Profile of Margetuximab: evidence to date in the targeted treatment of metastatic HER2-positive breast cancer I Schlam, R Nunes, F Lynce OncoTargets and therapy, 471-478, 2022 | 12 | 2022 |
| Efficacy, safety, low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal … P Shah, CJ Glueck, N Goldenberg, S Min, C Mahida, I Schlam, ... Lipids in Health and Disease 16, 1-12, 2017 | 11 | 2017 |
| Left ventricular assist devices in patients with active malignancies I Schlam, AY Lee, S Li, FH Sheikh, R Zaghlol, B Basyal, C Gallagher, ... Cardio Oncology 3 (2), 305-315, 2021 | 9 | 2021 |
| Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases? I Schlam, SM Tolaney Oncotarget 12 (9), 873, 2021 | 9 | 2021 |
| Best of the year: Advanced breast cancer in 2023 I Schlam, M Chavez-MacGregor The Breast 74, 103677, 2024 | 7 | 2024 |
| Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study F Lynce, C Mainor, RN Donahue, X Geng, G Jones, I Schlam, H Wang, ... Nature communications 15 (1), 2691, 2024 | 7 | 2024 |
| Emerging targeted therapies for early breast cancer I Schlam, P Tarantino, S Morganti, F Lynce, D Trapani, EL Mayer, ... Drugs 82 (14), 1437-1451, 2022 | 7 | 2022 |
| HOLA COVID-19 study: evaluating the impact of caring for patients with COVID-19 on cancer care delivery in Latin America C Bernabe-Ramirez, AI Velazquez, C Olazagasti, C Decat Bergerot, ... JCO global oncology 8, e2100251, 2022 | 7 | 2022 |